Treatment Improves Outcome For BCL6 Positive Patients
Elevated endometrial BCL6 expression is associated with lower clinical pregnancy rate, and live birth rate as well as a higher miscarriage rate. Recently published data on treatment outcomes is helping to back up what we already know about ReceptivaDx and its ability to identify new pathways for those with failed IVF history and recurrent pregnancy loss.
A prospective, cohort study design at a university associated infertility clinic evaluated the effect of surgical or medical treatment before embryo transfer in women with elevated endometrial BCL6 expression and suspected endometriosis.
Each subject had to have an abnormal BCL6 result defined by an elevated HSCORE>1.4, in addition to a minimum of one year of unexplained infertility (UI). All participants had undergone endometrial biopsy and immunostaining for BCL6 before the transfer, during a cycle of assisted reproductive technology (ART). The control group went untreated, while the others had either medical suppression or laparoscopy. Live birth rate (LBR), clinical pregnancy rate (CPR), implantation rate (IR), and miscarriage rates were compared between the treatment and control groups.
Women undergoing laparoscopy for endometriosis, and those treated by medical suppression had substantially higher live birth rates compared to no treatment. In addition to proving out that hormone suppression therapy was as effective as surgery, the miscarriage rate was significantly lower in treated patients as well. View the study here and schedule a consultation today!